The Global Emphysema Treatment Market size is expected to reach $6.05 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
Due to the excessive inflammation of the alveoli, emphysema is also known as chronic obstructive disease. This is because the condition causes both breathing and exhalation to slow down. Damage caused by emphysema to the air sacs may result in a change in the form of the air sacs or, more often, their destruction. This leads to a reduction in the amount of gas that is exchanged in the lungs, which in turn causes trouble breathing. This occurs because the damage to the alveoli results in inadequate room for air to enter the sacs, which causes air to get trapped within the alveoli.
By treating the patient with bronchodilators and steroids, it is possible to alleviate the patient's shortness of breath and cut down on the required hospitalizations. Chronic obstructive pulmonary disease (also known as COPD) is the third most significant cause of mortality globally, accounting for 3.23 million deaths in 2019. This information comes from the World Health Organization. Countries with low and intermediate incomes are responsible for about 90 percent of all COPD-related fatalities in people under the age of 70. (LMIC). COPD is caused by long-term exposure to toxic gases and particles with individual variables such as events that impact the formation of the lungs in infancy and heredity. Chronic obstructive pulmonary disease (COPD) results in ongoing and progressively worsening respiratory symptoms, such as difficulty breathing, coughing, and producing phlegm.
Other symptoms may include but are not limited to anxiety, sadness, weariness, difficulty sleeping, and weight loss. Emphysema is often misdiagnosed since the symptoms it displays are also associated with a variety of other lung illnesses and other health issues. The difficulty breathing brought on by emphysema may worsen over time and lead to a condition known as a chronic obstructive pulmonary disease (COPD).
The global healthcare industry has seen a disruption in processes due to the COVID-19 pandemic. The sickness has caused several different sectors, including numerous different sub-domains of the healthcare industry, to close their doors temporarily. On the other hand, the COVID-19 pandemic had a beneficial influence on the development of the market. Patients infected with the coronavirus basically suffer from the same symptoms as those with chronic obstructive pulmonary disease (COPD). These symptoms include difficulty breathing and an inadequate supply of oxygen-rich blood to the lungs and the rest of the body. As a result, the demand for drugs used to cure chronic obstructive pulmonary disease accelerated during the pandemic.
Tobacco consumption is one of the most significant challenges to the world's public health that it has ever encountered, and it is responsible for the deaths of many individuals. According to projections made by the World Health Organization, tobacco use results in more than 8 million deaths each year. More than 7 million of these fatalities are directly attributable to the use of tobacco products, while around 1.2 million are attributable to the exposure of non-smokers to second-hand smoke. The habit of smoking cigarettes almost often brings on emphysema. In addition, there is evidence that chronic exposure to other lung irritants, such as passive smoking, may also contribute to the development of COPD. As a result of the growing number of people who smoke tobacco throughout the globe, it is projected that the need for emphysema treatment will also rise in the years to come.
The most prevalent contributors to air pollution are combustion appliances found in homes, motor vehicles, industrial sites, and forest fires. In addition, particulate matter, carbon monoxide, nitrogen dioxide, ozone, and sulphur dioxide are significant pollutants that concern the public's health. Air pollution, both outside and inside, is a significant contributor to various illnesses and is one of the leading causes of death and disability worldwide. In addition, the World Health Organization (WHO) estimates that approximately 2.4 billion people are subjected to potentially harmful levels of air pollution in their homes as a result of their use of polluting open fires or simple stoves for cooking that are fueled by kerosene, biomass (wood, animal dung, and crop waste), and coal. These types of cooking methods produce dangerous levels of air pollution.
It is possible to support a diagnosis of advanced emphysema with an X-ray of the chest and rule out other potential reasons for shortness of breath. However, because of the prohibitively high prices and limited financial resources, many hospitals in underdeveloped countries cannot invest in diagnostic imaging equipment. Furthermore, because of the strong demand for diagnostic procedures, particularly in low-income countries, hospitals who do not have the financial resources to purchase brand-new imaging systems that are on the bleeding edge of technology decide instead to employ imaging systems that have been rebuilt. As a result, throughout the time that is anticipated, this aspect will constitute a substantial obstacle to the expansion of the market for infectious respiratory illness diagnostics.
Based on Medication Type, the Emphysema Treatment Market is segmented into Bronchodilators, steroids, and others. In the emphysema treatment market in 2021, the bronchodilators segment accounted for the largest revenue share. Bronchodilators are a class of drugs that relax the muscles in the lungs, which makes breathing easier, and widens the airways, which also makes breathing easier (bronchi). The expansion of this market segment may be attributed to an increase in the demand for bronchodilators as a therapy for emphysema and increased knowledge about the condition.
Based on the distribution channel, the Emphysema Treatment Market is classified into online providers, drug stores & retail pharmacies, and hospital pharmacies. The online providers segment registered a considerable revenue share in the emphysema treatment market in 2021. This may be linked to the fact that there has been an increase in demand for online providers that provide pharmaceuticals for the treatment of emphysema. This eliminates the need for patients to go to hospitals for treatment, contributing to the market expansion. In addition, a growing number of online platforms for medicine delivery is also driving the market. This is another factor that is driving the industry.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 4 Billion |
| Market size forecast in 2028 | USD 6.05 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 6.1% from 2022 to 2028 |
| Number of Pages | 167 |
| Number of Tables | 260 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Medication Type, Distribution Channel, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on region, the Emphysema Treatment Market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2021, the Asia Pacific region accounted for a significant revenue share in the emphysema treatment market. This is because of several variables, including an increase in spending in producing high-quality medications for emphysema. The increasing use of different triple combination formulations for the treatment of emphysema is also driving the expansion of the market. In addition, due to an increase in the number of people who smoke, India has the highest chronic obstructive pulmonary disease (COPD) rate. These factors combine to make Asia-Pacific an attractive need for emphysema treatment.
Free Valuable Insights: Global Emphysema Treatment Market size to reach USD 6.05 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
By Medication Type
By Distribution Channel
By Geography
The global Emphysema Treatment Market size is expected to reach $6.05 billion by 2028.
Rising Number Of Tobacco Consumers are driving the market in coming years, however, Expenses Incurred For Imaging Equipment restraints the growth of the market.
AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
The expected CAGR of the Emphysema Treatment Market is 6.1% from 2022 to 2028.
The Drug Stores & Retail Pharmacies market acquired maximum revenue share in the Global Emphysema Treatment Market by Distribution Channel in 2021, thereby, achieving a market value of $3.2 billion by 2028.
The North America market dominated the Global Emphysema Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2.7 billion by 2028.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
